Skip to main content
. 2020 Feb 4;11:24. doi: 10.3389/fphar.2020.00024

Figure 2.

Figure 2

(A) Schematic illustration to demonstrate the structures of CCM-coated, R837-loaded, mannose-modified PLGA nanoparticles (NP-R@M-M) and their immune-stimulant functions as a nanovaccine. (B) In vitro DC activation by various nanovaccine formulations. (C) In vivo fluorescence images of mouse hind legs after intradermal injection of fluorescent-labeled NP-R@M or NP-R@M-M at three different times. (D) Schematic illustration of a tumor challenge experimental design. (E) B16-OVA tumor volume curves after pretreatment with various nanovaccine formulations (n ≥ 5). (F) Percentages of CD107a+ cells among all T cells. (***P < 0.001, *P < 0.05). Reproduced with permission from (Yang et al., 2018). Copyright @ American Chemical Society.